As the building blocks of life processes, amino acids also are used in drug discovery. Not only are they the foundation of protein structures, but they also take part in hundreds of biochemical processes, and they are a crucial molecular component in drug development. And of all these amino acids, unnatural amino acids (UAAs) are becoming a growing force in the field of drugs. Because of their specific chemical structure and structure, UAAs could enhance the stability, selectivity and activity of drug molecules and thus the effectiveness and safety of drugs. More specifically in nascent areas like protein engineering, antibody drug development and targeted therapy, use of non-natural amino acids offers a more malleable scaffold for design, spurring new directions in drug discovery.
Unnatural amino acids refer to those amino acids that are not commonly found in natural protein synthesis, and are typically introduced through chemical synthesis or genetic engineering techniques. These amino acids differ from natural ones in their chemical structure and can be specifically modified at positions such as the side chain, amino group, or carboxyl group, thus imparting new chemical functions or physical properties. The introduction of unnatural amino acids allows researchers to achieve greater flexibility in protein design, creating molecules with specific functions, enhanced stability, or new interaction capabilities. For example, selenium-containing selenocysteine (Sec) plays an important role in catalytic reactions, while amino acids with special functional groups can be used in targeted therapies, drug delivery, or biomedical imaging. The widespread application of unnatural amino acids has advanced the development of protein engineering, drug discovery, and biomedical research, opening up new and innovative application scenarios.
BOC Sciences is a manufacturer and supplier of unnatural amino acids that provide tailored solutions to a range of industries including pharmaceuticals, biotechnology and materials science. We are very strict with our quality and accuracy and offer various synthetic and D-amino acids and isotopically labeled amino acids as an extension of the non-natural amino acids. Our experts apply state-of-the-art methods of chemical synthesis, enzymatic processes, and biotechnological engineering to develop pure compounds for the desired applications. These synthetic amino acids are vital for drug design, peptides, protein engineering, and creating new biomaterials.
Name | CAS | Catalog | Price |
O-Phospho-L-tyrosine | 21820-51-9 | BAT-005712 | Inquiry |
3-Nitro-L-tyrosine | 621-44-3 | BAT-007839 | Inquiry |
4-Amino-L-phenylalanine | 943-80-6 | BAT-007853 | Inquiry |
2-Nitro-L-phenylalanine | 19883-75-1 | BAT-006759 | Inquiry |
4-Methyl-L-phenylalanine | 1991-87-3 | BAT-007875 | Inquiry |
3-(2-Naphthyl)-L-alanine | 58438-03-2 | BAT-007802 | Inquiry |
Unnatural amino acids are becoming a vital component of drug discovery. These amino acids can be added into proteins or peptides, modifying their shape and function, thus making them more stable, selective and bioactive. Unnatural amino acids also spur the discovery of new medications, and have broad promise for cancer therapy, antiviral agents and biopharmaceuticals. Using rational design and synthesis, synthetic amino acids offer new avenues for drug discovery.
One useful use for unnatural amino acids in the search for drugs is as inhibitors of drug targets. Most disease arises and develops as a direct consequence of dysfunctional activity of specific enzymes or proteins, and unnatural amino acids inhibit that activity by binding to those targets and thus acting as drugs. In cancer therapy, for instance, histone deacetylases (HDACs) are prime targets. Their abnormal activity generates dysfunctional gene expression and fuels tumour cells' proliferation. Some synthetic amino acids may attach to the target areas of HDACs, inhibiting deacetylation, leading to differentiation and death in tumour cells that induce anticancer effects.
For peptide drugs, for example, adding nonnatural amino acids can dramatically enhance stability and target specificity. Natural peptides are prone to enzymatic degradation in the body, are unstable and have difficulty bridging biological barrier including cell membranes, leading to poor bioavailability and limited therapeutic potential. Unnatural amino acids are stable to enzymatic digestion because of their special properties, which makes them ideal for stabilising peptide drugs in the body. Moreover, some synthetic amino acids also have beneficial membrane permeability, which makes it easier for peptide medications to get into cells, and hence to be targeted. Moreover, by inserting specific unnatural amino acids into peptides, the drug can be redesigned and turned on to bind to receptors or cell surface markers for targeted therapy.
Unnatural amino acids are also used to construct antibody-drug conjugates (ADCs). ADCs are complexes bonded chemically between monoclonal antibodies and small-molecule medications that use the antibody's affinity to target the drug precisely to the cells of a tumour or other disease, making the drug more effective and less toxic to healthy tissue. It is possible to bind to the antibody or drug molecule with unnatural amino acids, allowing for unique and stable binding that creates a strong ADC structure. For instance, some unnatural amino acids have functional groups (such as alkyne or azide groups) which quickly form stable covalent bonds with corresponding functional groups in the drug molecules via click chemistry reactions, improving the stability and efficiency of ADCs.
The introduction of non-natural amino acids has opened new directions for protein engineering, particularly in drug discovery. By replacing natural amino acids, researchers can not only finely tune the three-dimensional structure of proteins but also impart entirely new biological functions. These functions include enhanced stability, specificity, stronger receptor binding capabilities, and the ability to trigger specific cellular responses. For example, non-natural amino acids can enhance the stability or solubility of proteins in the body by modifying their hydrophobic or hydrophilic properties. Additionally, using the unique functional groups of non-natural amino acids, researchers can insert bio-markers (such as fluorescent or radioactive labels) into proteins, which is crucial for drug screening and pharmacological research. These modifications significantly improve the targeting ability of protein drugs, especially in antibody drug development, where antibodies can more precisely recognize and bind to target antigens, thereby enhancing efficacy and reducing adverse reactions. The introduction of non-natural amino acids has also played a key role in vaccine development. In vaccine design, researchers can replace specific natural amino acids to make the antigen epitopes more immunogenic, thereby enhancing the immune response to the vaccine.
The application of non-natural amino acids in drug screening and high-throughput screening (HTS) platforms has significantly improved screening efficiency and accuracy. By introducing non-natural amino acids, researchers can design protein or peptide molecules with unique physicochemical properties, enhancing their binding affinity and selectivity for targets. This allows for the rapid identification of highly active, low-toxicity candidate molecules in high-throughput screening, reducing false positive results. Additionally, non-natural amino acids can be used to construct diverse chemical libraries or library proteins, improving the comprehensiveness of the screening process. By labeling non-natural amino acids with techniques such as fluorescence, radioactivity, or affinity tags, researchers can more accurately monitor molecular interactions in real-time, optimizing the screening process. With the combination of efficient screening platforms and intelligent data analysis, the use of non-natural amino acids is driving drug discovery towards a more precise and efficient future.
The synthesis of non-natural amino acids is a key technology in modern biochemistry and drug development. Compared to natural amino acids, non-natural amino acids usually possess unique chemical properties, which can be synthesized through chemical or biosynthetic methods. Synthesis techniques involve chemical reactions, enzyme catalysis, genetic engineering, and other approaches, enabling the efficient production of specialized amino acids for drug development, protein engineering, and materials science.
Chemical synthesis is one of the main methods for preparing unnatural amino acids. Through various organic chemical reactions, structurally diverse unnatural amino acids can be synthesized. Common chemical synthesis methods include asymmetric synthesis and transition metal-catalyzed synthesis. Asymmetric synthesis utilizes chiral catalysts or chiral auxiliaries to selectively synthesize unnatural amino acids with specific chirality. For example, using chiral catalysts in asymmetric hydrogenation reactions can convert non-chiral substrates into chiral unnatural amino acids. Transition metal-catalyzed synthesis, on the other hand, leverages the catalytic activity of transition metal catalysts to promote various chemical reactions, achieving efficient synthesis of unnatural amino acids. For instance, palladium-catalyzed cross-coupling reactions can link different organic molecular fragments to form complex unnatural amino acid structures.
In addition to chemical synthesis, biological synthesis is another important approach for preparing unnatural amino acids. Biological synthesis methods primarily use biotechnology techniques such as microbial fermentation and enzyme catalysis to synthesize unnatural amino acids through metabolic pathways or enzymatic reactions within organisms. Microbial fermentation involves cultivating specific microbial strains in fermentation tanks and controlling fermentation conditions to induce the large-scale synthesis of unnatural amino acids. For example, certain engineered strains, after genetic modification, can efficiently synthesize unnatural amino acids like β-amino acids. Enzyme catalysis, on the other hand, utilizes the catalytic specificity of enzymes to convert natural amino acids or other substrates into unnatural amino acids. For instance, transaminase catalysis can facilitate the transamination reaction between keto acids and amino acids to generate the corresponding unnatural amino acids.
Although unnatural amino acids offer many advantages in drug discovery, their research and application face several challenges. Firstly, the synthesis of unnatural amino acids is complex and costly. Due to their diverse and intricate structures, traditional chemical synthesis methods often require multiple steps and complicated reaction conditions, resulting in low synthesis efficiency and yields, which increase production costs. Additionally, the metabolic and excretion characteristics of unnatural amino acids within the body are not fully understood, which presents challenges for their safety assessment and pharmacokinetic studies in drug development. In the body, unnatural amino acids may be metabolized into other substances or excreted, and the unknown nature of their metabolic products and excretion pathways may impact the drug's efficacy and safety.
However, the research and application of unnatural amino acids also present significant opportunities. With the continuous advancement of science and technology, new synthesis methods and biotechnological approaches are emerging, offering vast potential for the efficient synthesis and application of unnatural amino acids. For example, gene editing technologies and synthetic biology methods can be used to modify microorganisms or cells to synthesize unnatural amino acids more efficiently, thereby reducing production costs. At the same time, the introduction of unnatural amino acids opens up more possibilities and innovation in drug development. Researchers can design drug molecules with higher selectivity, stronger activity, and better stability, utilizing the unique properties of unnatural amino acids to meet clinical treatment needs. Furthermore, unnatural amino acids can be combined with other technologies, such as DNA-encoded library technology, further expanding their application in drug discovery. By linking unnatural amino acids to DNA-encoded molecules, large-scale DNA-encoded unnatural amino acid libraries can be created for high-throughput screening and drug discovery, improving the efficiency and success rate of drug development.
In conclusion, unnatural amino acids play a unique and crucial role in drug discovery. They can serve as inhibitors for drug targets, enhance the stability and targeting of drugs, and be used in the development of antibody-drug conjugates, showing great potential for a wide range of applications. While there are challenges in their synthesis and application, the ongoing development of scientific technology will continue to lead to breakthroughs in the research and application of unnatural amino acids. Future research can focus on developing more efficient synthesis methods, studying the metabolic and excretion properties of unnatural amino acids in the body, and exploring more innovative applications in drug discovery, thereby contributing significantly to the advancement of drug development and meeting clinical treatment needs.
** Recommended Products **
Name | CAS | Catalog | Price |
Tyrosine O-sulfate | 956-46-7 | BAT-015229 | Inquiry |
2-Aminoisobutyric Acid | 62-57-7 | BAT-005802 | Inquiry |
N-Methyl-L-alanine hydrochloride | 3913-67-5 | BAT-004069 | Inquiry |
4-(Aminomethyl)-L-phenylalanine | 150338-20-8 | BAT-007844 | Inquiry |
N-Methyl-L-valine hydrochloride | 2480-23-1 | BAT-004075 | Inquiry |
L-α-Aminobutyric acid | 1492-24-6 | BAT-005615 | Inquiry |
O-tert-Butyl-L-serine | 18822-58-7 | BAT-004174 | Inquiry |
N-Methyl-DL-leucine hydrochloride | 2566-33-8 | BAT-003617 | Inquiry |
L-2-Allylglycine Hydrochloride | 195316-72-4 | BAT-015023 | Inquiry |
N-Methyl-L-serine hydrochloride | 2480-26-4 | BAT-003933 | Inquiry |